Evolus, Inc. (EOLS) fair value analysis
Nasdaq · Updated 2026-10-19
EOLS price how computed
Valuation status
Awaiting full valuationEOLS's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once EOLS's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $7.10
- Sector
- Healthcare
- 12-month range
- $3.94–$9.30
- Market cap
- $469M
- From 52-week high
- -23.7%
- Shares outstanding
- 66M
- Rank in Healthcare by quality score
- #109 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Evolus, Inc. is a medical aesthetics company that develops and commercializes injectable aesthetic products for physicians and patients. The company operates primarily in the United States and also maintains a presence in select international markets.
EOLS currently ranks #109 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $469M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $316M
- Net margin
- -10.8%
- EPS (TTM)
- $-0.33
- Gross margin
- 68.0%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 22.7%
- Shares outstanding
- 66M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $8.12
- 200-day average
- $6.19
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 2 beat, 5 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▲ beat (+58.3%)
2025-12 ▼ miss (-64.6%)
2025-09 ▲ beat (+23.1%)
2025-06 ▼ miss (-188.9%)
2025-03 ▼ miss (-21.4%)
2024-12 ▼ miss (-37.7%)
2024-09 ▼ miss (-63.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 1 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $15
- Target vs last price
- +111.3%
What our data shows for EOLS
- Shares are trading in the middle of their 12-month price range of $3.94–$9.30.
- The 14-day relative strength index sits at a neutral 37.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- EOLS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent EOLS news
TickrTrends' derived news-sentiment signal for EOLS is currently leaning positive, computed from recent coverage.
- AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (manilatimes.net, 2026-10-09)
- Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram Post (gurufocus.com, 2026-10-02)
- FDA Flags Evolus (EOLS) for Misleading Jeuveau Promotion on Instagram (gurufocus.com, 2026-10-02)
What people are saying
Follow the EOLS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for EOLS showed a shift in trend momentum this week as the 50/200-day trend state moved from uptrend to mixed. This change reflects a transition in the stock's intermediate-term directional bias. The valuation verdict remains awaiting full valuation.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is EOLS stock undervalued?
EOLS's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is EOLS's TickrTrends verdict?
EOLS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once EOLS's own trailing P/E history validates under our standards.
How does EOLS compare to other Healthcare stocks?
EOLS ranks #109 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is EOLS overbought or oversold?
EOLS's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does EOLS report earnings next?
EOLS's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does EOLS usually beat earnings estimates?
Over its last 8 reported quarters EOLS beat the consensus estimate 2 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about EOLS?
Of 6 analysts covering EOLS, 5 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $15 (+111.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.